The Association between Conventional Antidepressants and the Metabolic Syndrome
- 1 September 2010
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 24 (9) , 741-753
Abstract
Major depressive disorder is a prevalent recurrent medical syndrome associated with inter-episodic dysfunction. The metabolic syndrome is comprised of several established risk factors for cardiovascular disease (i.e. abdominal obesity, dyslipidaemia, dysglycaemia and hypertension). The criterion items of the metabolic syndrome collectively represent a multi-dimensional risk factor for cardiovascular disease and type 2 diabetes mellitus. Extant evidence indicates that both major depressive disorder and the metabolic syndrome, albeit distinct, often co-occur and are possibly subserved by overlapping pathophysiology and causative mechanisms. Conventional antidepressants exert variable effects on constituent elements of the metabolic syndrome, inviting the need for careful consideration prior to treatment selection and sequencing. Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome.Keywords
This publication has 180 references indexed in Scilit:
- Depression and the metabolic syndrome: gender-dependent associationsDepression and Anxiety, 2007
- Duloxetine versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic PainJournal of Palliative Medicine, 2006
- Comparison of the Effects of Amitriptyline and Flunarizine on Weight Gain and Serum Leptin, C Peptide and Insulin Levels when used as Migraine Preventive TreatmentCephalalgia, 2005
- Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive ageGynecological Endocrinology, 2005
- Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight lossInternational Journal of Obesity, 1997
- Usefulness of Fluoxetine in Obese Non‐Insulin‐Dependent Diabetics: A Multicenter StudyObesity Research, 1996
- No Specific Effect of Fluoxetine Treatment on Fasting Glucose, Insulin, Lipid Levels, and Blood Pressure in Healthy Men with Abdominal ObesityObesity Research, 1994
- Fluoxetine in the Treatment of Obese Type 2 Diabetic PatientsDiabetic Medicine, 1994
- Stress and the IndividualArchives of internal medicine (1960), 1993
- Imipramine and weight gain during the treatment of recurrent depressionJournal of Affective Disorders, 1990